Why the study?
To investigate the effect of chronic grape seed extract supplementation on blood pressure and aortic stiffness among overweight and obese males.
Does chronic grape seed extract supplementation reduce blood pressure and aortic stiffness in overweight and obese males?
Does chronic grape seed extract supplementation reduce blood pressure and aortic stiffness in overweight and obese males?
Short-term grape seed extract supplementation may serve as a dietary intervention to reduce arterial pressure and aortic stiffness at rest and during exercise in overweight and obese males.
GSE supplementation reduces MAP and aortic stiffness at rest and exercise; extends evidence for dietary interventions in overweight males.
We investigated the effect of chronic grape seed extract (GSE) on blood pressure and aortic stiffness (AoS) among overweight and obese males. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), stroke volume (SV), cardiac output (Q), total vascular conductance (TVC), and AoS were measured during two submaximal cycling exercises (40% and 60% VO2max), after 7 consecutive days of GSE or placebo (PL) ingestion with one week washout period. Compared with PL, GSE supplementation significantly decreased MAP at rest (85 ± 3 mmHg vs. 82 ± 3 mmHg), 40% (102 ± 3 mmHg vs. 99 ± 3 mmHg), and 60% workloads (109 ± 3 mmHg vs. 107 ± 3 mmHg) (P = 0.001, ES = 0.2). AoS was significantly reduced (13.0 ± 1.9 AU vs. 10.2 ± 1.0 AU) at rest (P = 0.002, ES = 0.6). Q was decreased at rest and across all workloads, but there were no significant differences (7.5 ± 0.4 L/min vs. 7.1 ± 0.4 L/min; 20.4 ± 1.2 L/min vs. 19.6 ± 0.9 L/min; 26.3 ± 1.1 L/min vs. 25.5 ± 1.6 L/min, respectively). GSE had no effect on HR, TVC, and SV. Our study indicates that chronic supplementation with GSE reduces arterial pressure at rest and during exercise primarily via the substantial reduction in AoS. Thus, GSE can be a dietary supplement to treat augmented blood pressure responses in obese and overweight males at rest and during exercise. Trial registration: ClinicalTrials.gov identifier: NCT04465110.
No takes yet. Share an insight, caveat, or question.
Dillon et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: